<h4>Background</h4>Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNF<i>α</i>) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant.<h4>Methods</h4>We performed a retrospective chart review to investigate outcomes among a series of post-liver-transplant PSC/IBD patients receiving anti-TNF<i>α</i> therapy at Henry Ford Health System ((HFHS), Detroit, MI).<h4>Results</h4>A total of five patients were treated with anti-TNF<i>α</i> agents for IBD after LT for PSC from 1993 through 2015. This evidence concerns the gene TNF and inflammatory bowel disease.